Literature DB >> 11981593

Nighttime versus daytime hypnotic self-administration.

Timothy Roehrs1, Alicia Bonahoom, Bonita Pedrosi, Frank Zorick, Thomas Roth.   

Abstract

RATIONALE AND
OBJECTIVES: Previous studies have shown that insomniacs self-administer hypnotics at high nightly rates. This study assessed whether insomniacs' self-administration of hypnotics extended to the daytime.
METHODS: Forty-four healthy men and women, 21-55 years old, with ( n=22) and without ( n=22) insomnia volunteered. They were randomized to one of two triazolam dose groups (0.125 or 0.25 mg) and their preference for placebo versus triazolam was assessed at night (2300 hours) and day (0900 hours) over 7 consecutive days in each phase. In both night and day phases of the study, subjects received triazolam or placebo in color-coded capsules on two sampling days or nights and then were forced to choose their preferred capsule on 5 subsequent days or nights. The order of day and night study phases and the placebo and triazolam sampling days was counterbalanced. In the night phase subjects went to bed from 2330 to 0730 hours and in the day phase they were tested for level of sleepiness-alertness at 1000, 1200, 1400, and 1600 hours by the multiple sleep latency test (MSLT) and mood and performance at 1100 and 1500 hours.
RESULTS: More triazolam was chosen at night than during the day. No dose differences in preferences at night versus day or between insomniacs and normals were found. Insomniacs did not differ in their triazolam preferences between night and day, while the normals chose triazolam less frequently during the day. Among insomniacs, 40% chose triazolam on >3 of the 5 days. On both screening and placebo sampling days, those with a high (>60%) daytime triazolam preference had greater average daily sleep latencies on the MSLT than those with a low (<50%) daytime triazolam preference (i.e. with a placebo preference). In the triazolam preference group, triazolam reduced daily MSLT latencies to the level of the placebo preference group.
CONCLUSIONS: This study shows that the minority of insomniacs who self-administer hypnotics during the day are physiologically aroused and the drug reduces their arousal suggesting that their daytime self-administration, like their night-time self-administration, is more consistent with therapy-seeking than drug-seeking behavior, at least for the short-term.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981593     DOI: 10.1007/s00213-002-1041-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  8 in total

Review 1.  Hypnotics: an update.

Authors:  Timothy Roehrs; Thomas Roth
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

2.  Twelve months of nightly zolpidem does not lead to dose escalation: a prospective placebo-controlled study.

Authors:  Timothy A Roehrs; Surilla Randall; Erica Harris; Renee Maan; Thomas Roth
Journal:  Sleep       Date:  2011-02-01       Impact factor: 5.849

Review 3.  Insomnia pharmacotherapy.

Authors:  Timothy Roehrs; Thomas Roth
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

4.  Hyperarousal in insomnia: pre-sleep and diurnal cortisol levels in response to chronic zolpidem treatment.

Authors:  Timothy Roehrs; Thomas Roth
Journal:  Sleep Med       Date:  2019-04-25       Impact factor: 3.492

5.  Prevalence and Predictors of Prescription Sleep Aid Use among Individuals with DSM-5 Insomnia: The Role of Hyperarousal.

Authors:  Vivek Pillai; Philip Cheng; David A Kalmbach; Timothy Roehrs; Thomas Roth; Christopher L Drake
Journal:  Sleep       Date:  2016-04-01       Impact factor: 5.849

Review 6.  Sleep Disturbance in Substance Use Disorders.

Authors:  Timothy A Roehrs; Thomas Roth
Journal:  Psychiatr Clin North Am       Date:  2015-08-22

Review 7.  Sleep and alertness disturbance and substance use disorders: A bi-directional relation.

Authors:  Timothy Roehrs; Mohammad Sibai; Thomas Roth
Journal:  Pharmacol Biochem Behav       Date:  2021-02-12       Impact factor: 3.533

8.  Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation.

Authors:  Ariadna Amador; Salvador Huitron-Resendiz; Amanda J Roberts; Theodore M Kamenecka; Laura A Solt; Thomas P Burris
Journal:  PLoS One       Date:  2016-09-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.